News Archive

There is limited data available on Health Tech investing in general and even less related to early stage investing in the sector. IPHA set out to fill that gap by analyzing quarterly health tech investing data between 2010 through Q1 2018. We track both total investment dollars and deals completed over the period with additional analysis of the five quarters leading up to March 31, 2018. There is an unmistakeable trend reversal that started in Q1 2017 that is significant for both health tech entrepreneurs and investors.

Women and men almost equally shared all positions in the life sciences world, but women are not advancing in their biopharma careers at the same pace as men, according to a recent report by the Massachusetts Biotechnology Council and recruiting firm Liftstream. The wide gender gap higher up, though improved in recent years, persists: Women only hold a quarter of all C-suite level jobs, and less than 15% joined the board of directors.

Lupin has announced that it has partnered with Mylan to commercialize Enbrel (Etanercept) biosimilar. Under the terms of the agreement, Lupin will receive an up-front payment of $15mn and potential commercial milestones together with an equal share in net profits of the product. Mylan will commercialize Lupin’s Etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.

Venture investors poured more than $1 billion into agtech last year, and we are on pace to match or exceed that this year. The convergence of AI, cloud computing, big data and gene editing, with applications from soil to plants, foods to medicines, farm to table are driving investments. Discerning startups and investors will capitalize from the market’s current, numerous opportunities.

Changes are afoot at GE. The company will separate GE Healthcare into a standalone company.

Kieran Murphy, the president and CEO of GE Healthcare, will continue at the helm of the business, which offers medical imaging, biomanufacturing and data analytics capabilities, among other services.

Carisma Therapeutics, formerly Carma Therapeutics, is working on a new onco-immunotherapy approach for treating cancer patients with solid tumors.

Without fanfare, the University of Pennsylvania has agreed to invest up to $50 million over the next three years in at least 10 biotech companies, the Inquirer has learned.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $80 million of its shares of common stock. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $12 million of its shares of common stock. All of the shares to be sold in the offering are to be sold by Senseonics.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today introduced seamless next-generation sequencing (NGS) solutions for a wide range of hereditary diseases on the GeneReader NGS System, the complete Sample to Insight NGS solution for any lab worldwide.

Hospitals in D.C. and Baltimore rank among the best in the nation, according to a new list released by U.S. News & World Report.

Overall, Children’s National Medical Center in D.C. ranked No. 5 and John’s Hopkins Children’s Center in Baltimore ranked No. 8 on the “honor roll,” which lists the best-performing children’s hospitals across 10 pediatric specialties including neonatal care, neurology, cancer and cardiology.